← Leaderboards
Nirali Shah
Division Of Basic Sciences - Nci
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at Division Of Basic Sciences - Nci
Same institution · by research overlap
Others in their field
Top investigators on “Child”
- Barbara Driver · Westat, Inc.$244,454,458
- Sharon A Nachman · Johns Hopkins University$212,395,175
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$195,214,889
- George R Seage · Abt Associates, Inc.$189,009,744
- Carol Nesel · Westat$188,148,170
- Elizabeth A Thom · George Washington University$170,579,744
Research focus
ChildYoung AdultRelapseDisease RemissionCar T Cell TherapyToxic EffectImmunotherapeutic AgentChimeric Antigen Receptor T CellsFutureHematologic NeoplasmsImmunotherapyRefractoryResponseAntigensCollaborationsT-LymphocyteBiologicalCd22 GeneNovel TherapeuticsImproved OutcomeCellsInfusion ProceduresProgramsLeukemia
Grant awards (16)
Comprehensive Interrogation of Toxicity Profiles Associated with Novel CAR T-cell Constructs$834,260
ZIA · FY2025 · CA · contact PI
Development of Novel Approaches to Optimize CAR T-cell Therapies for B-cell Malignancies$834,260
ZIA · FY2025 · CA · contact PI
Development of Novel Immunotherapeutic Strategies for Myeloid Malignancies$715,080
ZIA · FY2025 · CA · contact PI
Development of Novel Approaches to Optimize CAR T-cell Therapies for B-cell Malignancies$1,023,609
ZIA · FY2024 · CA · contact PI
Comprehensive Interrogation of Toxicity Profiles Associated with Novel CAR T-cell Constructs$767,708
ZIA · FY2024 · CA · contact PI
Development of Novel Immunotherapeutic Strategies for Myeloid Malignancies$767,708
ZIA · FY2024 · CA · contact PI
Clinical Development of Novel Therapies for Acute Lymphoblastic Leukemia$1,329,439
ZIA · FY2023 · CA · contact PI
Clinical Development of Immunotherapies for Rare Hematologic Maligancies$886,293
ZIA · FY2023 · CA · contact PI
Development of Novel Therapies for Acute Lymphoblastic Leukemia$943,000
ZIA · FY2022 · CA · contact PI
Clinical Development of Immunotherapies for Rare Hematologic Maligancies$628,666
ZIA · FY2022 · CA · contact PI
Development of Novel Therapies for Acute Lymphoblastic Leukemia$876,050
ZIA · FY2021 · CA · contact PI
Clinical Development of Immunotherapies for Rare Hematologic Maligancies$219,012
ZIA · FY2021 · CA · contact PI
Development of Novel Therapies for Acute Lymphoblastic Leukemia$822,033
ZIA · FY2020 · CA · contact PI
Clinical Development of Immunotherapies for Rare Hematologic Maligancies$205,508
ZIA · FY2020 · CA · contact PI
Immunotherapeutic approaches to treat pediatric hematologic malignancies$283,351
ZIA · FY2019 · CA · contact PI
Clinical Development of Novel Agents for Relapsed Acute Lymphoblastic Leukemia$70,837
ZIA · FY2019 · CA · contact PI